AstraZeneca's SATURN "Moon Shot" Pitting Crestor Against Lipitor Misses The Mark
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts, however, say the data miss is not a huge setback for AstraZeneca.
You may also be interested in...
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.
Battle Of The Blockbusters: Lipitor Vs. Crestor In Atherosclerosis Progression Study Begins
1,300-patient, two-year Cleveland Clinic trial measures rate of regression of coronary disease.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.